News | Prostate Cancer | November 25, 2015

Studies Find Decline in Rates of PSA Screening, Early-Stage Prostate Cancer

November 25, 2015 — Two studies in the November 17 issue of the Journal of the American Medical Association (JAMA) examine the change in prostate-specific antigen (PSA) screening and prostate cancer incidence before and after the 2012 U.S. Preventive Services Task Force (USPSTF) screening recommendations.

Ahmedin Jemal, D.V.M., Ph.D., of the American Cancer Society, Atlanta, and colleagues examined trends in stage-specific prostate cancer incidence and PSA-based screening for men 50 years and older subsequent to the 2008 and 2012 USPSTF recommendations using the most recent population-based incidence and nationally representative screening data. Prostate cancer incidence in men 75 years and older substantially decreased following the 2008 USPSTF recommendation against PSA-based screening for this age group. It has been unknown whether incidence has changed since the USPSTF recommendation against screening for all men in May 2012.

The researchers determined prostate cancer incidence (newly diagnosed cases/100,000 men 50 years of age and older) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries. The PSA screening rate was determined for men 50 years and older without a history of prostate cancer who responded to the 2005 (n = 4,580), 2008 (n = 3,476), 2010 (n = 4,157), and 2013 (n = 6,172) National Health Interview Survey.

The researchers found that prostate cancer incidence per 100,000 in men 50 years and older (n = 446,009 in SEER areas) was 535 in 2005, 541 in 2008, 505 in 2010, and 416 in 2012; rates began decreasing in 2008 and the largest decrease occurred between 2011 and 2012, from 498 to 416. The number of men 50 years and older diagnosed with prostate cancer nationwide declined by 33,519, from 213,562 in 2011 to 180,043 in 2012. The decreases in incidence were evident in both non-Hispanic white and non-Hispanic black individuals and across regions.
The percentage of men 50 years and older reporting PSA screening in the past 12 months was 37 percent in 2005, 41 percent in 2008, 38 percent in 2010, and 31 percent in 2013. In relative terms, screening rates increased by 10 percent between 2005 and 2008 and then decreased by 18 percent between 2010 and 2013. Similar screening patterns were found in age subgroups 50 to 74 years and 75 years and older.

“Using the most recent population-based incidence and nationally representative self-reported PSA screening data, we report reductions in early-stage prostate cancer incidence and PSA-based screening rates in men 50 years and older, coinciding with the 2012 USPSTF recommendation against PSA-based screening,” the authors write. “Longer follow-up is needed to see whether these decreases are associated with trends in mortality.”

This project was supported by the Intramural Research Department of the American Cancer Society. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

In another study, Jesse D. Sammon, D.O., of Brigham and Women’s Hospital, Boston, and colleagues examined PSA screening data from the 2000, 2005, 2010, and 2013 National Health Interview Survey to determine the prevalence and determinants of screening before and after the 2012 USPSTF recommendations (draft released October 2011), as well as the association between the new USPSTF recommendations and the prevalence of screening.

The final study population included 20,757 men. The prevalence of PSA screening was 34 percent in 2000 and 2005. Between 2010 and 2013, the prevalence decreased from 36 to 31 percent overall. In a pooled analysis, survey year 2013 (vs. 2010) was associated with lower odds of PSA screening. However, declines were seen only in men younger than 75 years vs men 75 and older. The largest declines were seen among men age 50-54 years (from 23 percent to 18 percent) and among men 60-64 years of age (from 45 to 35 percent). After adjusting for patient factors, there were significant reductions in PSA screening associated with the 2012 USPSTF recommendations.

“The 2008 USPSTF recommendations against PSA screening in men aged 75 years or older have not been associated with changes in screening practices. However, we found a decrease in the prevalence of PSA screening following the 2012 recommendations, particularly in men younger than 75 years,” the authors write.

“These findings using nationally representative data suggest that younger men may be altering health care behavior at a higher rate than older men following the new USPSTF recommendations, changes in clinician PSA screening practices have occurred in response to the policy change, or both. Alternatively, the findings may reflect the broad effects of the economic recession on health care use or a delayed response to the 2008 guidelines.”

 

Related Content

High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 sc

Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 scan (arrow in C), later verified on pathology as true malignant lesion. Images created by J. Kuten et al., Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

News | Prostate Cancer | May 12, 2020
May 12, 2020 — The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting mali
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...
M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center

News | Prostate Cancer | March 05, 2020
March 5, 2020 — Using a combination of...
Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...